Volume 2 Supplement 3

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Meeting abstracts

This supplement has not been sponsored.

Society for Immunotherapy of Cancer 29th Annual Meeting. Go to conference site.

National Harbor, MD, USA6-9 November 2014

Content type: Oral presentation

Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma

Authors: Laura A Johnson, John Scholler, Takayuki Ohkuri, Akemi Kosaka, Prachi R Patel, Shannon E McGettigan, Arben Nace, Pramod Thekkat, Andreas Loew, Taylor J Chen, Joseph A Fraietta, Avery D Posey, Alina C Boesteanu, Alexandria P Cogdill, Boris Engels, Reshma Singh…

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O1

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Modulating immunometabolism of tumor specific CD8 T cells to enhance T cell based therapy for cancer

Authors: Madhusudhanan Sukumar, Jie Liu, Gautam Mehta, Luca Gattinoni, Toren Finkel and Nicholas Restifo

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O2

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Toward cell transfer immunotherapy against patient-specific mutations in gastrointestinal cancers

Authors: Eric Tran, Mojgan Ahmadzadeh, Alena Gros, Simon Turcotte, Paul F Robbins, Yong Chen Lu, Yong Li, John Wunderlich, Jared Gartner, Katherine Hogan, James Yang and Steven Rosenberg

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O3

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform

Authors: Shamim Ahmad, Mikayel Mkrtichyan, Rasha Abu Eid, Rajeev Shrimali, Atbin Doroodchi and Samir N Khleif

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O4

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Vaccine targeting HIF1A in triple negative breast cancer

Authors: Denise Cecil, Daniel Herendeen, Meredith Slota, Yushe Dang, Megan O'Meara, Ekram Gad, Lauren Rastetter, Marlese Koehnlein and Mary L Disis

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O5

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Melanoma progression is associated with NK cell exhaustion

Authors: Ines Pires da Silva, Anne Gallois, Sonia Jimenez-Baranda, Ana Anderson, Vijay Kuchroo, Iman Osman and Nina Bhardwaj

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O6

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Authors: Kavita Dhodapkar, Rakesh Verma, Mario Sznol, Chandra Sekhar Boddupalli, Scott Gettinger, Harriet Kluger, Madhav Dhodapkar and Rituparna Das

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O7

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma

Authors: Michael Postow, Manuarii Manuel, Phillip Wong, Jianda Yuan, Marlene Noel, Anais Courtier, Nicolas Pasqual and Jedd D Wolchok

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O8

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

Authors: Simon Dovedi, Amy Adlard, Grazyna Lipowska-Bhalla, Conor McKenna, Sherrie Jones, Eleanor Cheadle, Ian Stratford, Edmund Poon, Michelle Morrow, Ross Stewart, Hazel Jones, Robert W Wilkinson, Jamie Honeychurch and Tim Illidge

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O9

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity

Authors: Leticia Corrales, Laura Hix Glickman, Sarah M McWhirter, David B Kanne, Kelsey E Sivick, Edward Lemmens, Justin J Leong, Ken Metchette, Thomas W Dubensky and Thomas Gajewski

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O10

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma

Authors: Ayelet Sivan, Leticia Corrales and Thomas Gajewski

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O11

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

Authors: Elisabeth Quoix, Lecia Sequist, John Nemunaitis, Thaddeus Beck, Piotr Jaskiewicz, Jean-Philippe Oster, Arnaud Scherpereel, Erzsébet Juhász, Zsuzsanna Mark, Rosa Alvarez, Saiama Waqar, Joseph Potz, Nandagopal Vrindavanam, Anton Melnyk, Helen Ross and Jean-Marc Limacher

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O12

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Mechanisms of TIGIT-driven immune suppression in cancer

Authors: Sema Kurtulus, Kaori Sakuishi, Huiyuan Zhang, Nicole Joller, Dewar Tan, Mark Smyth, Vijay Kuchroo and Ana Anderson

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O13

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

FcgRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via Ipilimumab-dependent ADCC in melanoma patients

Authors: Emanuela Romano, Monika Kusio-Kobialka, Periklis G Foukas, Helene Bichat, Petra Baumgaertner, Christiane Meyer, Pierluigi Ballabeni, Olivier Michielin, Benjamin Weide, Pedro Romero and Daniel E Speiser

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O14

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity

Authors: Stefani Spranger, Riyue Bao and Thomas Gajewski

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O15

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

Tumor derived stress triggers C/EBPβ homologous protein (Chop) expression in myeloid derived suppressor cells (MDSC) and mediates immunosuppressive activity

Authors: Paul Thevenot, Rosa Sierra, Patrick Raber and Paulo Rodriguez

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O16

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial

Authors: Laurent Humeau, Cornelia Trimble, Matthew Morrow, Xuefei Shen, Michael Dallas, David Weiner, Jean Boyer, Jian Yan, Kimberly Kraynyak, Albert Sylvester, Mary Giffear, Kathy Marcozzi-Pierce, Divya Shah, Kate Broderick, Amir Khan, Jessica Lee…

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O17

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression

Authors: Amy Moran, Fanny Polesso and Andrew Weinberg

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O18

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

TCR repertoire divergence reflects micro-environmental immune phenotypes in glioma

Authors: Jennifer Sims, Boris Grinshpun, Yaping Feng, Justin Neira, Jorge Samanamud, Peter Canoll, Peter Sims, Yufeng Shen and Jeffrey Bruce

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O19

Published on: 6 November 2014
- View Full Text
- View PDF
Content type: Oral presentation

PD-L1 expression correlates with immune response in a Phase I trial of CCL21 gene modified dendritic cell therapy in lung cancer

Authors: Jay M Lee, Edward B Garon, Mi-Heon Lee, Gerald Wang, Dörthe Schaue, Felicita Baratelli, Fereidoun Abtin, Robert Suh, William D Wallace, Gang Zeng, Sherven Sharma and Steven M Dubinett

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 3):O20

Published on: 6 November 2014
- View Full Text
- View PDF

Journal for ImmunoTherapy of Cancer

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Meeting abstracts

Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and phase I trial of CART-EGFRvIII in glioblastoma

Modulating immunometabolism of tumor specific CD8 T cells to enhance T cell based therapy for cancer

Toward cell transfer immunotherapy against patient-specific mutations in gastrointestinal cancers

Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform

Vaccine targeting HIF1A in triple negative breast cancer

Melanoma progression is associated with NK cell exhaustion

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

Direct activation of STING in the tumor microenvironment with synthetic cyclic dinucleotide derivatives leads to potent and systemic tumor-specific immunity

Evidence implicating the commensal microbiota in shaping anti-tumor immunity in melanoma

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

Mechanisms of TIGIT-driven immune suppression in cancer

FcgRIIIA (CD16)-expressing monocytes mediate the depletion of tumor-infiltrating Tregs via Ipilimumab-dependent ADCC in melanoma patients

Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity

Tumor derived stress triggers C/EBPβ homologous protein (Chop) expression in myeloid derived suppressor cells (MDSC) and mediates immunosuppressive activity

DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial

OX40 agonist immunotherapy expands tumor reactive CD8 T cells with a unique T cell receptor repertoire and synergizes with PDL-1 blockade to promote tumor regression

TCR repertoire divergence reflects micro-environmental immune phenotypes in glioma

PD-L1 expression correlates with immune response in a Phase I trial of CCL21 gene modified dendritic cell therapy in lung cancer

Official journal of

Follow

2016 Journal Metrics

Journal for ImmunoTherapy of Cancer

Contact us

Preview